Unlocking Relief: Essential Insights into Nasal Polyp Treatments for Better Health

Summary and Overview

Nasal polyps are benign inflammatory growths commonly associated with chronic rhinosinusitis with nasal polyps (CRSwNP) and related conditions like cystic fibrosis and aspirin-exacerbated respiratory disease. They cause nasal obstruction, loss of smell, facial pressure, and reduced quality of life, driven by type 2 inflammation involving cytokines IL-4, IL-5, and IL-13. Affecting around 320 million people globally, CRSwNP requires multidisciplinary management.

Traditional treatments include corticosteroids (intranasal and systemic) and endoscopic sinus surgery (ESS), but recurrence and incomplete symptom control often occur. New biologic therapies—dupilumab, mepolizumab, and omalizumab—target key inflammatory pathways, reducing polyp size and symptom burden, with emerging agents like tezepelumab showing additional promise. Biologics generally have favorable safety profiles, though long-term effects and cost remain concerns. Personalized approaches integrating pharmacologic advances, surgery, and supportive care are essential.

Clinical Presentation and Diagnosis

Nasal polyps cause nasal congestion, rhinorrhea, loss of smell, and sometimes facial pressure or complications affecting the eyes. Diagnosis relies on clinical history, nasal endoscopy, and imaging—especially CT scans—to assess extent and exclude other causes. Allergy and asthma history guide management strategies.

Treatment Approaches

Initial treatment focuses on intranasal corticosteroids to reduce inflammation and polyp size. Oral corticosteroids may be used short-term for severe cases but carry systemic risks. Antibiotics and saline rinses support symptom relief. For refractory or severe cases, biologic therapies targeting type 2 inflammation (dupilumab, mepolizumab, omalizumab) provide effective alternatives by inhibiting cytokines or IgE involved in polyp growth.

ESS is indicated when medical therapy fails or obstruction is severe, aiming to remove polyps and improve topical treatment access. However, polyps often recur, necessitating postoperative corticosteroids and sometimes biologics to reduce relapse risk.

Supportive care includes digital health tools and patient education to improve treatment adherence and outcomes.

Comparative Effectiveness and Patient Selection

Randomized controlled trials show biologics improve nasal polyp scores and symptoms with good safety profiles, offering options for patients with bilateral polyps, prior surgery, or contraindications to surgery. ESS remains effective and safe but may be complemented or replaced by biologics in selected cases. Treatment choice depends on disease severity, comorbidities, safety, and patient preferences. Further research is needed on optimal treatment sequencing, cost-effectiveness, and biomarker-driven therapy selection.

Side Effects and Risks

Intranasal corticosteroids are generally safe. Oral corticosteroids have systemic side effects limiting long-term use. Biologics may cause injection site reactions, headache, conjunctivitis, or eosinophilia but are well tolerated overall. ESS carries risks including mild postoperative bleeding, infection, and rare serious complications, with low rates of significant intraoperative bleeding or blood transfusion.

Prognosis, Future Directions, and Supportive Care

Management focuses on controlling inflammation and preventing recurrence, with local corticosteroids as a cornerstone. Biologics targeting type 2 pathways have improved severe case outcomes, and newer agents targeting upstream cytokines like TSLP show potential for broader effects. Digital health tools and multidisciplinary care enhance adherence and personalized management.

Ongoing challenges include defining biologics’ roles, long-term safety, cost, and patient selection. Lifestyle measures such as infection prevention and patient education complement medical treatment, contributing to better quality of life and reduced relapse risk.